Disulfiram Improves the Anti-PD-1 Therapy Efficacy by Regulating PD-L1 Expression via Epigenetically Reactivation of IRF7 in Triple Negative Breast Cancer

Cancer Statistics, 2021

(2021) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer

(2021) Dobrin Draganov et al.   npj Breast Cancer

Targeting FROUNT with disulfiram suppresses macrophage accumulation and its tumor-promoting properties

(2020) Yuya Terashima et al.   Nature Communications

Decitabine Augments Chemotherapy-Induced PD-L1 Upregulation for PD-L1 Blockade in Colorectal Cancer

(2020) Kevin Chih-Yang Huang et al.   Cancers

DNMT1: A Key Drug Target in Triple-Negative Breast Cancer

(2020) Keng Wong Kah   SEMINARS IN CANCER BIOLOGY

Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer

(2019) Triparna Sen et al.   Cancer Discovery

HDAC3 inhibition up-regulates PD-L1 expression in B-cell lymphomas and augments the efficacy of anti-PD-L1 therapy

(2019) Siyu Deng et al.   MOLECULAR CANCER THERAPEUTICS

Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial

(2019) Leonie Voorwerk et al.   NATURE MEDICINE

Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade

(2019) Steve Lu et al.   JAMA Oncology

DHA-SBT-1214 Taxoid Nanoemulsion and Anti-PD-L1 Antibody Combination Therapy Enhances Anti-Tumor Efficacy in a Syngeneic Pancreatic Adenocarcinoma Model

(2019) Gulzar Ahmed et al.   MOLECULAR CANCER THERAPEUTICS

lncRNA OSTN-AS1 May Represent a Novel Immune-Related Prognostic Marker for Triple-Negative Breast Cancer Based on Integrated Analysis of a ceRNA Network

(2019) Zijian Liu et al.   Frontiers in Genetics

Mechanisms regulating PD-L1 expression on tumor and immune cells

(2019) Shuming Chen et al.   Journal for ImmunoTherapy of Cancer

Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer

(2019) Athanasios Mavratzas et al.   Future Oncology

IFNAR1 Controls Autocrine Type I IFN Regulation of PD-L1 Expression in Myeloid-Derived Suppressor Cells

(2018) Wei Xiao et al.   JOURNAL OF IMMUNOLOGY

Decitibine improve the efficiency of anti-PD-1 therapy via activating the response to IFN/PD-L1 signal of lung cancer cells

(2018) Qi Lai et al.   ONCOGENE

Cancer immunotherapy using checkpoint blockade

(2018) Antoni Ribas et al.   SCIENCE

Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations

(2018) Jun Gong et al.   Journal for ImmunoTherapy of Cancer

The Protein Expression of PDL1 Is Highly Correlated with Those of eIF2α and ATF4 in Lung Cancer

(2018) Liang-Che Chang et al.   DISEASE MARKERS

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors

(2018) Ming Yi et al.   Molecular Cancer

Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression

(2018) Xin Jin et al.   MOLECULAR CELL

Type I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer

(2018) Qiang Lan et al.   ONCOGENE

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy

(2018) Razvan Cristescu et al.   SCIENCE

Identification of DNA methylation associated gene signatures in endometrial cancer via integrated analysis of DNA methylation and gene expression systematically

(2017) Chuandi Men et al.   Journal of Gynecologic Oncology

Combination therapy strategies for improving PD-1 blockade efficacy: a new era in cancer immunotherapy

(2017) P. S. Chowdhury et al.   JOURNAL OF INTERNAL MEDICINE

Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4

(2017) Zdenek Skrott et al.   NATURE

BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1

(2017) Simon J. Hogg et al.   Cell Reports

Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications

(2017) Martina Musella et al.   OncoImmunology

Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study

(2016) Roisin M. Connolly et al.   CLINICAL CANCER RESEARCH

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

(2016) Rita Nanda et al.   JOURNAL OF CLINICAL ONCOLOGY

Predictive biomarkers for checkpoint inhibitor-based immunotherapy

(2016) Geoffrey T Gibney et al.   LANCET ONCOLOGY

PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas

(2016) Aaron Goodman et al.   Nature Reviews Clinical Oncology

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells

(2016) Chunwan Lu et al.   OncoImmunology

MEXPRESS: visualizing expression, DNA methylation and clinical TCGA data

(2015) Alexander Koch et al.   BMC GENOMICS

Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses

(2015) Katherine B. Chiappinelli et al.   CELL

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Disulfiram inhibits TGF-β-induced epithelial-mesenchymal transition and stem-like features in breast cancer via ERK/NF-κB/Snail pathway

(2015) Dan Han et al.   Oncotarget

Alterations of immune response of non-small cell lung cancer with Azacytidine

(2015) John Wrangle et al.   Oncotarget

Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers

(2015) Huili Li et al.   Oncotarget

Disulfiram modulates stemness and metabolism of brain tumor initiating cells in atypical teratoid/rhabdoid tumors

(2014) Seung Ah Choi et al.   NEURO-ONCOLOGY

DNA methylation profiles of long- and short-term glioblastoma survivors

(2013) Thoraia Shinawi et al.   Epigenetics

Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape

(2012) Bradley N Bidwell et al.   NATURE MEDICINE

Triple-Negative Breast Cancer

(2010) William D. Foulkes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth

(2010) Jianqing Lin et al.   PROSTATE

Phase I Study of Epigenetic Modulation with 5-Azacytidine and Valproic Acid in Patients with Advanced Cancers

(2008) F. Braiteh et al.   CLINICAL CANCER RESEARCH